This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Double-Blind, Placebo-Controlled Study of the Efficacy of Reboxetine and Citalopram as Adjuncts to Atypical Antipsychotics for Negative Symptoms of Schizophrenia

Judith Usall, MD, PhD; Raquel López-Carrilero, MS; Raquel Iniesta, PhD; Mercedes Roca, MD; Montserrat Caballero, MD; Roberto Rodriguez-Jimenez, MD, PhD; Cristina Oliveira, MD, PhD; Miguel Bernardo, MD, PhD; Iluminada Corripio, MD, PhD; Santiago Durán Sindreu, MD; Jose Carlos González Piqueras, MD, PhD; Ana Espliego Felipe, MD; Blanca Fernandez de Corres, MS; Angela Ibáñez, MD, PhD; and Raúl Huerta, MD; for the Abordaje Sí­ntomas Negativos Esquizofrenia (ASINE) Group

Published: June 27, 2014

Article Abstract

Objective: In this study, we assessed the efficacy of 2 pharmacodynamically different antidepressants, citalopram (a selective serotonin reuptake inhibitor) and reboxetine (a norepinephrine reuptake inhibitor), as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia.

Method: We performed a 6-month, multicenter, double-blind, randomized, placebo-controlled clinical trial. The recruitment period was from November 2008 to December 2011. The sample comprised 90 patients with a diagnosis of schizophrenia (DSM-IV criteria) who exhibited negative symptoms. The patients were recruited from 10 centers in different cities of the Spanish State. The primary efficacy measure was change in score on the negative subscale of the Positive and Negative Syndrome Scale (PANSS) between baseline and 6-month assessment. Other efficacy measures were changes in the PANSS subscales and total score, as well as the Scale for the Assessment of Negative Symptoms (SANS) subscales and total score.

Results: For statistical analysis, we employed mixed-effects models. We did not find statistically significant differences between the placebo group and the 2 treatment groups at 6-month assessments for the PANSS total (P = .6511), any PANSS subscale (negative [P = .5533], positive [P = .1723], or general psychopathology [P = .2083]), or the SANS (P = .5884). Cohen d measure showed a small effect size below the 0.5 threshold for all comparisons.

Conclusions: In conclusion, our results do not support adjunctive use of citalopram or reboxetine with risperidone or olanzapine for the treatment of negative symptoms in schizophrenia.

Trial Registration: identifier: NCT01300364

Volume: 75

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF